EGFR and non-small cell lung carcinoma: Lastly, in the phase III PALOMA-3 trial, including patients with EGFR-mutated NSCLC after disease progression to osimertinib, a modest decrease in the risk of VTE in patients treated with subcutaneous amivantamab compared to intravenous amivantamab, both in combination with lazertinib, was observed [22].